Skip to content
AdAdvertisement
Value Science Weekly — health economics and market access, in your inbox

Latest News — Page 11

AI healthcare regulation

Artificial Intelligence And Machine Learning

UK AI Healthcare Commission Report Calls for L-Plates Regulation

An independent UK commission has published its recommendations for regulating AI in healthcare. The report calls for staged approvals and continuous real-world monitoring, alongside stronger enforcement powers for the MHRA. #SyenzaNews #AI #Healthcare #MarketAccess

Syenza TeamRead ›
Saúde em Perspetiva debates AI in Portuguese healthcare: interoperability first, clear red lines, and why it is still mo

Artificial Intelligence And Machine Learning

AI in Portuguese Healthcare: What Should Portugal Want It to Do?

Nova SBE’s Saúde em Perspetiva podcast asks what Portugal’s National Health Service should want from AI, and where the red lines sit. #SyenzaNews #DigitalHealth #AIinHealthcare

Syenza TeamRead ›
Sandoz Bio100 biosimilars plan featured image

Biologics And Biosimilars

Sandoz Bio100 Biosimilars Plan Targets 100 Products by 2040

Sandoz has put a date on its golden decade for biosimilars. The Bio100 plan targets more than 100 biosimilars by 2040, about 80% coverage of biosimilar-addressable LoE value from 2035, and a doubling of 2025 net sales. #SyenzaNews #MarketAccess #Biosimilars #ValueCreation

Syenza TeamRead ›
semaglutide asthma attacks

Clinical Practice

Semaglutide Linked to Fewer Asthma Attacks in UK Data

Real-world UK data presented at ERS 2026 link semaglutide to fewer asthma attacks and COPD exacerbations. The indication stays metabolic, but the signal raises a real question for value and access teams. #SyenzaNews #MarketAccess #GLP1 #Respiratory

Syenza TeamRead ›
Camizestrant and CDK4/6 inhibitor for ESR1-mutated breast cancer

Clinical Practice

FDA Grants Accelerated Approval to Camizestrant for ESR1-Mutated Breast Cancer

Camizestrant (Etcamah) gains accelerated FDA approval for ESR1-mutated advanced breast cancer, with median progression-free survival of 16 months versus 9.2 months in SERENA-6. #SyenzaNews #BreastCancer #FDA #Oncology

Syenza TeamRead ›
Featured image for South Africa lenacapavir PrEP rollout article

Diseases

South Africa Initiates 55,123 People on Twice-Yearly Lenacapavir PrEP

South Africa has initiated 55,123 people on twice-yearly lenacapavir PrEP in the programme’s first 94 days. Demand is strongest in Gauteng and KwaZulu-Natal; branded supply, second-dose retention and the 2027 generic tender are the real constraints. #SyenzaNews #HIVPrevention #Lenacapavir #MarketAccess

Syenza TeamRead ›
Novartis and The Max Foundation Mark 25 Years of Cancer Access in LMICs

Diseases

Novartis and The Max Foundation Mark 25 Years of Cancer Access in LMICs

Novartis and The Max Foundation mark 25 years of partnership that has delivered cancer treatment to more than 100,000 patients across 71 LMICs. The next test is whether the model can carry a broader oncology portfolio and transition to country funding.

#SyenzaNews #MarketAccess #GlobalHealth

Syenza TeamRead ›
proteomic aging clocks

Clinical Practice

Six Proteomic Aging Clocks Detect Age Reversal With Rentosertib

An Insilico Medicine phase 2a trial found six proteomic aging clocks all detected lower biological age in patients treated with rentosertib, an AI-designed drug for idiopathic pulmonary fibrosis. #SyenzaNews #Proteomics #AgingClocks #DrugDiscovery #IPF

Syenza TeamRead ›
Ziltivekimab cardiovascular programme halted

Cardiovascular And Metabolic Diseases

Novo Nordisk Halts Ziltivekimab Heart Failure Trials

Novo Nordisk has stopped the two remaining ziltivekimab heart failure trials after a futility review, leaving ARTEMIS as the last anti-inflammatory cardiovascular outcomes bet. #SyenzaNews #MarketAccess #Cardiology #HTA

Syenza TeamRead ›
lenacapavir local manufacturing

Clinical Practice

Aspen Exits Lenacapavir Local Manufacturing, Backs Merck’s Monthly Oral PrEP

Aspen Pharmacare has walked away from local lenacapavir manufacturing over the lack of guaranteed volumes, and is instead backing Merck’s once-monthly oral PrEP pill, alimatravir. #SyenzaNews #HIV #PrEP #MarketAccess

Syenza TeamRead ›
Aspen Pharmacare FY2026 earnings rebound and generic semaglutide rollout

Diabetes

Aspen Pharmacare Bets on Manufacturing Rebound and Generic Semaglutide

Aspen Pharmacare posted 22% normalised earnings growth and is betting on a manufacturing rebound and a generic semaglutide rollout for FY2027. #SyenzaNews #Pharma #GLP1 #MarketAccess #SouthAfrica

Syenza TeamRead ›
The MFN drug pricing policy is delaying new medicine launches across Europe. Christoffer Frendesen on the silence, the d

Clinical Practice

Trump’s MFN Drug Pricing Policy Is Cutting Europe’s Access to New Medicines

Trump’s Most Favored Nation drug pricing policy is already delaying new medicine launches in Europe. Brussels journalist Christoffer Frendesen unpacks the silence, the data, and why it may outlast the Trump presidency. #SyenzaNews #MarketAccess #DrugPricing

Syenza TeamRead ›
Medicare GLP-1 Bridge

Clinical Practice

Medicare GLP-1 Bridge Tops 500,000 Users in Its First Two Months

US Medicare is paying for obesity GLP-1s for the first time, and more than 500,000 seniors signed up in the first two months. Our latest breaks down the $245 price, the $50 copay, and what it means for Lilly and Novo Nordisk. #SyenzaNews #MarketAccess #GLP1 #Medicare

Syenza TeamRead ›
European Medicines Agency pre-submission interactions model pilot

Clinical Practice

EMA Pre-Submission Pilot Adds Earlier Dialogue to Curb Premature Filings

EMA’s voluntary pre-submission pilot opens in September 2026. It adds earlier, more structured dialogue between applicants, rapporteurs and the Agency to curb premature filings. #SyenzaNews #MarketAccess #RegulatoryAffairs

Syenza TeamRead ›
autoimmune CAR-T safety

Diseases

Autoimmune CAR-T Safety Test Emerges After Trial Pauses

Novartis and Bristol Myers Squibb have paused autoimmune CAR-T trials after inflammatory events and three deaths, putting the immune-reset thesis to its first real safety test. #SyenzaNews #CellTherapy #AutoimmuneDisease #MarketAccess

Syenza TeamRead ›
Four US operators explain US healthcare market access: who funds innovation, when a US hire pays off, why pilots stall,

Clinical Practice

US healthcare market access: what four operators told Canadian healthtech founders

CTS’s Global Horizon panel brought four US operators to Montréal to explain why the US healthcare market rewards commercial readiness over good technology, and what founders can do about it. #SyenzaNews #MarketAccess #HealthTech

Syenza TeamRead ›